



**DEPARTMENT OF HEALTH & HUMAN
SERVICES**

Food and Drug
Administration Rockville,
MD 20857

November 13, 2020

Michelle R. Ryder, Principal Consultant
Lachman Consulting Services, Inc.
1600 Stewart Ave, Suite 604
Westbury, NY 11590

Sent via email to: m.ryder@lachmanconsultants.com

Dear Petitioner:

Your petition to the Commissioner of Food and Drug Administration requesting to declare that the proposed drug product, Vancomycin Hydrochloride for Oral Solution EQ 125 mg (base)/5 mL is suitable for submission as an ANDA was received by this office on 11/13/2020.

It was assigned docket number FDA-2020-P-2187. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the suitability petition for filing is a procedural matter and in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Dynna Bigby
Supervisory Administrative Proceedings Officer
Dockets Management Staff
FDA/Office of Operations (OO)